Therapy-resistant hypertension: New aldosterone synthase inhibitor lowers blood pressure
In the Phase III Launch-HTN study, the aldosterone synthase inhibitor lorundrostat significantly reduced blood pressure in patients with previously uncontrolled hypertension compared to placebo.
Arzte zeitung
